Search

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

Read more

Uptake of CAR T cell therapy in Europe

Feb 05 2019 Posted in Advocacy news Tagged CAR T

Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

Publications

Subconjunctival injection of mesenchymal stromal cells protects the cornea in an experimental model of GVHD. Martínez-Carrasco R, Sánchez-Abarca LI, Nieto-Gómez C, García EM, Sánchez-Guijo F, Argüeso P, Aijón J, Hernández-Galilea E, Velasco A. Ocul Surf. 2019 Jan 7.

Read more

Survey Monitoring H2020 – your input is needed!

We need your input to improve Horizon 2020 and the next Research and Innovation Framework Programme of the European Union.

Read more

EHA-TSH Hematology Tutorial

EHA is joining the Turkish Society of Hematology (TSH) to organize the EHA-TSH Hematology Tutorial on T Cell Lymphomas. Date: June 29-30, 2024
Location: Ankara, Türkiye
Format: In-Person

Target audienceHematology fellows from Türkiye.

Read more

Publications

Experience With IVDR Implementation in Three Diagnostic Laboratories: Messages to EU Health Institutions, Diagnostic Healthcare Payers, and Authorities

Lubbers, Bart R. ; Dombrink, Isabel; Kalina, Tomas; Hofmans, Mattias; Bruun, Morten S. ; Stanworth, Simon J. ; Béné, Marie C.

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more